ZetaGen Therapeutics

Name

ZetaGen Therapeutics

Legal name

ZETAGEN THERAPEUTICS, INC.

Website

https://zetagen.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Syracuse

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Development: Pre-revenue clinical-stage biopharmaceutical company developing novel therapies for metastatic and primary breast cancer. No commercial products yet; revenue expected upon FDA approval of drug candidates.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

ZetaGen Therapeutics develops a proprietary Zeta Platform of drug-eluting carriers that deliver small-molecule therapies via a single intratumoral injection, targeting metastatic and primary breast cancer. The company's pipeline includes oncology candidates (ZetaMet for bone metastases, ZetaMAST for liver metastases, ZetaPrime for primary HR+ breast cancer) and a musculoskeletal franchise (ZetaFuse, ZetaSet, ZetaBase, ZetaDent) for bone healing and dental applications. Products are investigational and currently accessed only through clinical trials or FDA-approved Expanded Access programs.

Product overview

ZetaGen Therapeutics is a clinical-stage biopharmaceutical company developing the 'Zeta' proprietary drug delivery platform for intratumoral administration of tumoricidal therapies. The platform includes lead oncology candidates ZetaMet (Zeta-BC-003) for metastatic breast cancer to bone, ZetaMAST (Zeta-MBC-005) for breast cancer liver metastases, and ZetaPrime (Zeta-PBC-007) for primary HR+ breast cancer. The musculoskeletal division encompasses ZetaFuse for spinal fusions, ZetaSet for osteoporotic fractures, ZetaBase as bone void filler, and ZetaDent for dental applications. All oncology products utilize proprietary carriers designed to deliver compounds locally to reduce off-target toxicity while maximizing therapeutic efficacy.

Differentiator

Problem solved

Functional benefit

Brands

• Zeta Platform: Proprietary drug delivery platform for intratumoral administration of tumoricidal compounds
• ZetaMet (Zeta-BC-003)
• ZetaMAST (Zeta-MBC-005)
• ZetaPrime (Zeta-PBC-007)
• ZetaFuse (Zeta-ZF-002)
• ZetaSet
• ZetaBase
• ZetaDent

Products and services

• ZetaMet (Zeta-BC-003) First-of-its-kind synthetic small-molecule therapy delivered via proprietary controlled-release carrier for metastatic breast cancer to bone, designed to cease lytic activity, inhibit pain, and regenerate bone via single intratumoral injection without systemic limitations.
• ZetaMAST (Zeta-MBC-005) Proprietary drug-eluting hydrogel carrier for locoregional administration of small molecules in treatment of multifocal, unresectable liver metastases from breast cancer.
• ZetaPrime (Zeta-PBC-007) Neo-adjuvant treatment for primary HR+ breast cancer utilizing proprietary hydrogel-like lipid carrier for controlled release of small molecules including novel molecular entity and CDK4/6 inhibitors, designed for intratumoral administration to reduce off-target effects.
• ZetaFuse (Zeta-ZF-002) First synthetic, small-molecule osteo-inductive biologic designed to aid bone healing of spinal fusions across the complete spinal column (cervical, thoracic, lumbar).
• ZetaSet First synthetic osteo-inductive biologic designed specifically for treatment of osteoporotic fractures, high energy injuries with bone defects, and fractures of tibial plateau and plafond.
• ZetaBase Osteo-conductive and osteo-promotive therapy intended as bone void filler for bony voids or gaps not intrinsic to stability of bony structure; pending 510K approval.
• ZetaDent Osteo-inductive biologic intended to promote bone formation as part of localized ridge augmentation procedures prior to dental implant placement.

Quantifiable outcome

• Mean bone defect volume decreased 65.4% at Day 84 (p=0.0003)
• +6 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and supporting.

• University of British ColumbiacoreStrategic or Co-development PartnerClinical trial site for Phase 2a study (NCT05280067) evaluating ZetaMet for metastatic breast cancer to bone. Dr. Manraj Heran serves as principal investigator. Study completed enrollment of 10 subjects.
• University of British ColumbiacoreStrategic or Co-development PartnerClinical site for Phase 2a study (ZGMBC; NCT05280067) where preliminary topline results showed complete response in all treated lesions with no adverse events.
• McGill UniversitysupportingStrategic or Co-development PartnerClinical trial partnership for Phase 2a study examining safety and efficacy of ZetaMet for treatment of metastatic bone lesions in Stage 4 breast cancer patients.
• Nor Consult, LLC (NorCo)supportingImplementation/ SI/ Consulting PartnerProvided comprehensive clinical operations support for ZetaMet clinical study at University of British Columbia.
• Medical Medics IncorporatedsupportingImplementation/ SI/ Consulting PartnerDelivered centralized imaging services enabling rigorous data quality and standardized imaging assessments throughout the ZetaMet clinical trial.
• State University of New YorkcoreStrategic or Co-development PartnerZetagen exclusively licensed its platform technology from SUNY in 2016, providing the foundation for the Zeta Platform.
• Foley & Lardner LLPsupportingImplementation/ SI/ Consulting PartnerIntellectual property counsel maintaining collaborative relationship with Steve Maebius, Esq. Global reach and specialized expertise in Life Sciences IP and strategic counsel.
• Gilmartin Group, Inc.supportingOthersKiki Patel, Pharm. D., Principal at Gilmartin Group serves as investor relations contact for Zetagen Therapeutics.
• Debasish (Debu) Tripathy, MDcoreOthersProfessor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. Joined advisory board March 2024. Led clinical trials of new biologic therapies targeting HER2 and CDKs.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Puma Biotechnology: Puma Biotechnology develops and commercializes NERLYNX (neratinib) for HER2-positive breast cancer, making it a directly comparable clinical/commercial-stage breast cancer therapeutics company with similar indication focus and oncology pipeline depth.
• Olema Oncology: Olema Oncology is a clinical-stage biopharmaceutical company developing OP-1250 for HR+ breast cancer. Comparable to ZetaGen in stage, indication focus (breast cancer), and therapeutic innovation approach targeting underserved breast cancer populations.
• Radius Health: Radius Health developed bone-targeted therapeutics including TYMLOS (abaloparatide) for osteoporosis and elacestrant for breast cancer, making it directly comparable to ZetaGen's bone-focused pipeline (ZetaMet, ZetaFuse, ZetaSet) and breast cancer programs.
• Mersana Therapeutics: Mersana Therapeutics is a clinical-stage oncology company developing antibody-drug conjugates using its proprietary Dolasynthen and Immunosynthen platforms. Comparable to ZetaGen as a clinical-stage platform oncology company with multiple pipeline candidates and similar development stage.
• Bolt Biotherapeutics: Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing boltbody immune-stimulating antibody conjugates. Similar to ZetaGen in stage, oncology focus, and proprietary platform-based therapeutic approach with multiple pipeline candidates.
• CytomX Therapeutics: CytomX Therapeutics develops conditionally activated antibody therapeutics using its Probody platform. Comparable to ZetaGen as a clinical-stage platform oncology company with proprietary technology enabling targeted/localized drug delivery to reduce off-target effects.
• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide therapeutics for oncology using its proprietary Bicycle platform. Comparable to ZetaGen in being a clinical-stage platform biopharmaceutical company with novel drug-delivery/conjugation technology applied across multiple oncology indications.
• Oncternal Therapeutics: Oncternal Therapeutics is a clinical-stage oncology company developing zilovertamab for cancers including breast cancer. Comparable to ZetaGen in development stage, oncology focus, and pipeline diversification across multiple cancer types.

Broad incumbents

• Amgen: Amgen is a global biopharmaceutical leader with XGEVA (denosumab) for prevention of skeletal-related events in bone metastases from solid tumors. Directly comparable to ZetaGen's ZetaMet indication (bone metastases) but as a large incumbent with established oncology franchise.
• Bayer: Bayer developed Xofigo (radium-223 dichloride), the first approved alpha-particle therapy for castration-resistant prostate cancer bone metastases. Comparable to ZetaGen's bone metastases therapeutic focus but as a large incumbent with established radiopharmaceutical oncology franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ZetaGenTx
• LinkedInlinkedin.com/company/zetagen-therapeutics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZetaGen Therapeutics